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Pancreatic  ductal  adenocarcinoma  is characterized  by a poor  prognosis  and  a low  median  survival,
despite  improvements  observed  for  many  other  solid  tumours.  Intensive  research  efforts  have  been
undertaken  during  the  last  decades  to discover  new  prognostic  and  treatment  predictive  biomarkers
for pancreatic  ductal  adenocarcinoma.  The  mainstay  of  medical  treatment  for the  disease  has  been
the  well-tolerated  nucleoside  analogue,  gemcitabine.  The  only  targeted  agent  currently  used  in  pan-
creatic  ductal  adenocarcinoma  patients  is the  epithelial  growth  factor  receptor  inhibitor  erlotinib  in
combination  with  gemcitabine.  Recently,  treatment  regimens  such  as  a  combination  of  ﬂuorouracil-redictive marker
rognostic marker
leucovorin-irinotecan-oxaliplatin  (FOLFIRINOX)  and  the  combination  of nab-paclitaxel  with  gemcitabine
have  been  introduced  for metastatic  pancreatic  ductal  adenocarcinoma.  Although  these  treatment  regi-
mens signiﬁcantly  improve  survival  of  patients,  there  are  no good  predictive  biomarkers  available  that  can
be used  to identify  who  would  beneﬁt  most  from  them.  Therefore,  the  search  for predictive  biomarkers
that  would  facilitate  personalization  of  chemotherapy  is highly  relevant.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. Introduction
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst
rognoses amongst any type of cancer, with an overall 5-year sur-
ival rate of less than 5%, and a median survival time of less than
 months if untreated. Although PDAC accounts for less than 2% of
ew cancers, it is among the leading causes of cancer related mor-
ality as the vast majority of patients present with locally advanced
r metastatic disease. An incidence rate that is nearly equal to its
ortality rate highlights the lethal nature of the disease. The best
hance for curing the disease is early detection combined with a
adical surgical approach, which can lead to a 5-year survival rate
f approximately 20%, when combined with adjuvant chemother-
py [1]. Early detection is however hampered by the vagueness of
ymptoms and the lack of speciﬁc clinical markers of early stages of
DAC. In the present review, we provide an overview of the actual
arkers used in clinical practice from risk factors to prognostic
∗ Corresponding author at: Department of Surgical and Perioperative Sciences,
niversity of Umeå, 90185 Umeå, Sweden. Tel.: +46 90 785 0000;
ax: +46 90 785 1156; mobile: +46 70 375 8322.
E-mail address: malin.sund@surgery.umu.se (M.  Sund).
1 See Appendix A.
ttp://dx.doi.org/10.1016/j.dld.2015.11.001
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allmarkers, and explore the most promising ﬁelds of research in terms
of treatment selection and individualized therapy in PDAC.
2. Biological markers
As deﬁned by the NIH Biomarker Working Group, a biomarker
is “a characteristic objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes,
or pharmacologic responses to a therapeutic intervention” [2].
Biomarkers are divided into three categories: diagnostic, pro-
gnostic and predictive. A biomarker seldom belongs only to one
category, and many can have multiple functions (Fig. 1).
A biomarker that detects a disease or quantiﬁes its extent is a
possible diagnostic marker. Ideally, a diagnostic marker would be
non-invasive, inexpensive, and effective to identify high-risk pre-
malignant lesions. A prognostic marker provides information on
the likely course of the cancer disease in an untreated individual.
A predictive marker, ﬁnally, indicates the groups of patients who
probably will beneﬁt the most from a given therapy. With predic-
tive biomarkers it should be possible to select the therapy with the
highest likelihood of efﬁcacy to the individual patient. Therefore,
predictive markers are the basis for tailored treatment.
Although many studies have been conducted in order to identify
diagnostic, predictive and prognostic biomarkers in PDAC, only a
 rights reserved.
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Pig. 1. Summary of the relationships between risk factors, predictive, prognostic
nd  diagnostic markers.
ew markers have been routinely introduced into clinical practice.
he only biomarker approved by FDA is CA 19-9, despite having
everal limitations [3].
Finally, when looking at any disease development, risk factors
hat may  lead to a speciﬁc disease are of importance. PDAC is
ssociated to several risk factors, both inherited and non-inherited
Table 1), and the characterization of these may  contribute to an
arly diagnosis and identiﬁcation of new biomarkers.
. Risk factors for PDAC
.1. Non-inherited risk factors
The incidence of PDAC is strongly age-dependent and thus
mprovement in the lifespan means that the absolute frequency of
DAC will rise, especially in countries that have large ageing popu-
ations. The male-to-female incidence and mortality ratio of PDAC
s 1.1–2.0, even though no clear explanation for this is known [4].
Cigarette smoking is the leading preventable cause of PDAC and
s believed to account for 20% of PDACs [5]. Smoking shows a dose-
elated effect, and increases the risk of PDAC by 25% compared to
on-smokers [6–8].Chronic pancreatitis increases the risk of PDAC, with a cumu-
ative risk of 4% after 20 years [9]. For patients with hereditary
ancreatitis, the risk of PDAC approaches 40% after several decades
able 1
on-inherited risk factors for pancreatic ductal adenocarcinoma.
Risk factor Author Year 
Cigarette smoking Balckord et al. [2] 2009
Fuchs et al. [3] 1996
Silverman et al. [4] 1994
Chronic pancreatitis Lowenfels et al. [7] 1993
Lowenfels et al. [8] 1997
Age  Maisonneuve et al. [9] 2010 
Gender Wahi et al. [10] 2009 
Diabetes Chari et al. [11] 2008 
Diet Li et al. [13] 2009 
ABO group Wolpin et al. [14] 2010
Vogel et al. [15] 1970
Annese et al. [16] 1990
Amundadottir et al. [17] 2009
Occupational exposure Ojajärvi et al. [18] 2007 
Race  Curado et al. [19] 2007 
Infectious diseases Maisonneuve et al. [9] 2010 
DAC, pancreatic ductal adenocarcinoma; PMID, PubMed Identiﬁer; MR,  meta relative.isease 48 (2016) 223–230
of the initial onset of pancreatitis, and a paternal inheritance pat-
tern further increases the probability of developing PDAC [10].
A recent onset of diabetes can be an early symptom of PDAC and
is observed in approximately 30% of all patients [11]. A case–control
study conducted by Li et al. [12] demonstrated that diabetic patients
who used metformin had a reduced risk of PDAC when compared to
non-users, whereas patients using insulin therapy or insulin sec-
retagogues (sulfonylureas and meglitinides) had an increased risk of
PDAC.
Several studies have shown that obesity is associated with a
higher risk of PDAC. The PANSCAN consortium demonstrated that
obesity is associated with 20% higher risk of developing PDAC
[13]. Obesity may  have a role not only as risk factor, as shown in
young adults with high BMI, but can also inﬂuence the prognosis
of patients with PDAC especially at an older age [12].
Signiﬁcant variances in the frequency of PDAC exist between
races. In particular, black populations show a higher rate compared
with all other races [14]. Although an ethnic-speciﬁc difference in
the ability of detoxifying tobacco products has been accounted as
part of the genetic differences, non-genetic risk factors seem to have
a notable role.
Several studies have investigated a speciﬁc role of infectious
agents and PDAC. The strongest association has been reported for
Helicobacter pylori, with a meta-analysis of 7 studies that quantiﬁed
up to 65% the increased risk of PDAC.
Taken together, these non-genetic risk factors are not correlated
with speciﬁc types of PDAC and thus it is not easy use them as a
source for detection of novel biomarkers.
3.2. Inherited risk factors
Approximately 5–10% of individuals with PDAC report a family
history of the disease [15]. Many potential genes have been found
such as BRCA1,  BRCA2,  STK11/LKB1, PRSS1,  SPINK1, CDKN2A and APC
with a relative involvement in PDAC pathogenesis [16].
BRCA2 mutations are associated with breast and ovarian can-
cer, but are also associated with an increased risk of PDAC, with
a 3.5-fold (95% CI, 1.87–6.58) increased risk in mutations carri-
ers. Furthermore, the probability of a germline BRCA2 mutation
increases to between 6% and 12% in patients with PDAC who have at
least a ﬁrst-degree relative diagnosed with PDAC [17,18]. To date,
mutations in the BRCA2 genes are considered the most commonPeutz–Jeghers syndrome (PJS) is known to be associated with a
variety of cancers. Inherited mutations in the STK11/LKB1 gene are
responsible for up to 80% of cases. Patients with PJS have a greater
Description
Increased risk of 25%
Increased risk of 4–40%
90% of PDAC develops in population over 50 years of age
Male to Female ratio is 1.1 to 2.0
2-fold increased risk
20% higher risk in diet-induced obesity
Higher risk in non-O blood type
Chlorinated hydrocarbons solvents (MR  risk 2.21), insecticides (MR  risk 1.95)
Higher risk rate in Afro-Americans
Increased risk associated with H. pylori, hepatitis B virus and periodontal disease
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han 132-fold increased risk of developing PDAC [19]. These cancers
an progress through an intraductal papillary mucinous neoplasm
IPMN) precursor pathway.
Hereditary pancreatitis (HP) is a rare genetic disease, with
ermline mutations in the cationic trypsinogen gene (PRSS1), an
utosomal dominant form, and germline mutations in the serine
rotease inhibitor gene (SPINK1), an autosomal recessive form. The
ost common mutations of PRSS1 are R122H and N29I [20]. Indi-
iduals with HP have an approximately 53-fold increased risk for
DAC. Cumulative rates of pancreatic adenocarcinoma in patients
ith HP reach 30–40% by the age of 70 [12]. Most patients have a
lassic tubular type of inﬁltrating ductal adenocarcinoma.
Familial adenomatous polyposis (FAP) is an autosomal domi-
ant hereditary disease associated with PDAC, and is characterized
y the development of hundreds to thousands of colonic ade-
omatous polyps at an early age. Germline mutations in the
denomatous polyposis coli (APC) gene, a tumour suppressor gene,
re responsible for the disease. Patients with FAP may  have a 4-fold
ncrease in risk for PDAC [21]. In contrast to conventional ductal
denocarcinoma of the pancreas, both sporadic and FAP-associated
ancreatoblastomas lack KRAS2 and TP53 gene mutations. Instead,
ost cases harbour alterations in the APC/beta-catenin pathway
22].
Though the aforementioned factors could possibly serve as
otential prognostic markers for PDAC, further studies are needed
o establish such a potential.
. Diagnostic biomarkers for early detection of PDAC
.1. Biomarkers in clinical practice
The clinically most established and used biomarker is CA19-9,
hich lacks the desired sensitivity and speciﬁcity for both early
etection and establishing prognosis. In addition, a substantial pro-
ortion of patients do not express CA19-9.
.2. Biomarkers in pipeline
In a study of genes altered in PDAC, Harsha et al. recorded nearly
100 molecules overexpressed in both early neoplastic lesions and
n PDAC, including S100P,  MMP7,  MUC4,  FSCN1,  and MUC5AC [23],
ndicating that many potential biomarkers exist.
PDAC is characterized by an extensive stroma. Stroma plays
 crucial role in supporting the growth, angiogenesis and drug-
esistance of the tumour. SPARC is a protein involved in cell
atrix interactions, wound repair, and cell migration, and has been
eported to inhibit cancer growth. SPARC undergoes epigenetic
ilencing in many PDACs [24,25], and moreover SPARC produced by
eritumoural ﬁbroblasts was shown to be associated with poorer
rognosis for patients with PDAC. Unlike many genes that are over-
xpressed by both stromal cells and ductal cells, Galectin-1 and
RISP-3 are among the minority of molecules that have been clearly
escribed to be overexpressed only in the stroma. Öhlund et al. [26]
ave also demonstrated that type IV collagen, which is secreted
ainly by stellate cells, can stimulate PDAC cells to proliferate and
igrate. In addition, it can inhibit apoptosis through an autocrine
oop, supporting the tumour’s own growth and drug-resistant char-
cteristic. More recently, the possibility to combine conventional
nd stroma-derived markers in PDAC was published by Franklin
t al. [27] and as these are expressed in different compartments of
he cancer, a combination could increase sensitivity of CA19-9.Another potential marker is MIC-1,  which has been compared to
A19-9 for early detection of PDAC. Receiver operating characteris-
ic (ROC) curve analysis showed that MIC-1 was signiﬁcantly better
han CA19-9 in differentiating patients with PDAC from healthyisease 48 (2016) 223–230 225
controls (area under the curve (AUC) is 0.99 and 0.78, respectively;
p-value = 0.003), but not in distinguishing PDAC from chronic pan-
creatitis (AUC of 0.81 and 0.74, respectively; p-value = 0.63). The
conclusion was  that MIC-1,  indeed, is superior over CA19-9 in
detecting PDAC. However, the sample size was  small with only
50 specimens, and further validation is needed [28]. A monoclonal
antibody PAM4 that is reactive with a unique epitope expressed by
more than 85% of PDACs has also been characterized. Sensitivity
for detection of PDAC was  82%, with a false-positive rate of 5% for
healthy controls. Patients with advanced disease had signiﬁcantly
higher antigen levels than those with early-stage disease (p < 0.01),
with a diagnostic sensitivity of 91%, 86%, and 62% for stage 3/4,
stage 2, and stage 1 disease, respectively. This suggests that PAM4
should be considered as a potential screening biomarker. However,
validation on a clinically larger scale is needed [29].
Recent developments in proteomics have provided novel meth-
ods for detecting biomarkers [30]. Flight mass spectrometry
(MALDI-TOF/MS) with the aim of ﬁnding new metabolites repre-
senting novel serum biomarkers that could differentiate between
diabetes associated with PDAC and diabetes alone [31]. Three
metabolites were identiﬁed m/z 1465, 1206 and 1020. Of these,
m/z 1020 apparently discriminated patients with PDAC and dia-
betes from those with diabetes only. A clinical validation method
for biomarker identiﬁcation was  suggested. However, this new
screening method is subjected to further investigation on a larger
and multilateral scale.
In a proof-of-principle study, stool-based miRNA was  evaluated
for its feasibility as potential biomarkers for screening PDAC. Using
a subset of miRNAs dysregulated frequently in PDAC, the authors
had found that miR-21 and miR-155 were overexpressed, and
miR-216 was under ex-pressed in PDAC tissues, pancreatic juice
and stool specimens compared to their controls. In addition, good
reproducibility in miRNAs extraction and detection from stool and
pancreatic juice was  observed. The consistent expression of miR-
21, miR-155 and miR-216 among PDAC tissues, pancreatic juice and
stools demonstrated the feasibility of using stool miRNAs as non-
invasive tools for screening PDAC. Moreover, combination of two  or
three stool miRNAs (miR-21, miR-155 and miR-216) could provide
acceptable capacity for screening PDAC [32].
Since an invasive cancer is often associated with tumour
shedding, pancreatic juice is considered as a rich source of tumour-
associated proteins and mutant DNA, with associated genetic
changes. Earlier studies have evaluated conventional PDAC tumour
markers such as CA19-9, CEA and many others to detect PDAC.
However, modest sensitivity, speciﬁcity and accuracy are common
drawbacks [33]. Common markers such as mutant KRAS, p53 and
miDNA were also tried out but faced with signiﬁcant limitations,
including low sensitivity, high false positivity and low yield in the
event of pancreatic duct obstruction [34].
Salivary protein transcriptome using DNA microarray technique
identiﬁed that a combination of four messenger RNA biomarkers
(KRAS, MBD3L2, ACRV1, and DPM1) could essentially differentiate
cancer from normal patients with a relatively high sensitivity (90%)
and speciﬁcity (95%). Nevertheless, larger-scale proteomic analysis
of salivary secretions is needed and currently being evaluated [35].
Faecal K-RAS results gave a wide range of positive hits, from 20%
to 90%; besides, changes are also detected in up to 55% of benign
pancreatic conditions (inﬂammation, hyperplasia), in the normal
population (10–13%) and other non-pancreatic related diseases
(colorectal cancer, 60–80%). This makes it a relatively nonspeciﬁc
test [36]. Different combinations of markers generated increased
sensitivity and speciﬁcity, e.g. K-RAS with CA19-9 or CA-242. P53
is inferior compared to K-RAS because the more frequent aberrant
expression [37].
Other markers include MIC-1, CEACAM-1, REG-4, OPN, solu-
ble iC3b (siC3b) and TPS antigen [38]. The REG family comprises
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Table 2
Different therapeutic regimens and prognostic markers in pancreatic ductal adenocarcinoma.
Author Year Chemotherapy Prognostic markers Number of patients
Ueno et al. [102] 2000 Fluorouracil based, gemcitabine, cisplatin,
docetaxel, epirubicin, irinotecan
CRP, CA 19-9, ECOG PS, Albumin 103
Glen  et al. [103] 2006 N/A CRP, Albumin 187
Maréchal et al. [104] 2007 Gemcitabine based KPS score, Weight loss (10%), AST 99
Yi  et al. [50] 2011 Gemcitabine based CRP, Albumin, Liver metastasis, Ascites dissemination 298
Hamada et al. [51] 2014 Gemcitabine based Age, Sex, ECOG PS, Tumour size, Lymph node
metastasis, Distant metastasis
531
Xue  et al. [52] 2015 Gemcitabine based, S-1 ECOG PS, Ca 19-9, CRP 118
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spartate aminotransferase.
ecreted proteins, acting as trophic or anti-apoptotic factors in the
ancer growth regulation. Its increased sensitivity over CA19-9 and
he ability to distinguish from normal adults may  make it a suit-
ble diagnostic biomarker for early detection of PDAC, yet further
alidating studies are needed in clinical settings [39]. OPN is a gly-
ophosphoprotein normally produced and secreted into most body
uids by osteoblasts, macrophages, arterial smooth muscle cells,
arious epithelia, and activated T cells. OPN upregulation has been
ssociated with decreased survival in cancer patients [40]. SiC3b is a
omplement protein that is generated by the interaction of tumour
ells, antitumour antibodies. Marten et al. had reported that siC3b is
deal for postoperative surveillance, identifying early tumour recur-
ence [41]. Despite an exhaustive list of potential markers identiﬁed
n PDAC, few have reached clinical validation or proven to be advan-
ageous compared to CA19-9.
.3. Screening of high-risk populations
The best screening protocol for individuals at increased risk of
DAC is a major research focus. A primary example is the Cancer of
he Pancreas Screening 2 and 3 trials (CAPS2 and CAPS3). Patients
ho are 50 years of age or older, with three relatives diagnosed
ith PDAC, including at least one affected ﬁrst-degree relative, are
nrolled. About 10% of these had IPMN on endoscopic ultrasound
US). In the CAPS3 screening trial, pancreatic cystic lesions were
etected more frequently with endoscopic US (96%) and MRI  (81%)
han with CT (27%) [42,43]. Ideally novel markers should be tested
n these high-risk populations.
. Prognostic markers
The identiﬁcation of prognostic factors that can stratify patients
ccordingly to clinical and biological markers may  help to select
dequate treatment strategies. Among the different prognostic fac-
ors presented below, although being promising, few have yet been
ranslated into clinical practice. Consideration of performance sta-
us and CA19-9 remain the main prognostic factor when it comes
o PDAC patients (Table 2).
.1. Performance status
Several studies demonstrated that baseline performance status
PS) is an important independent prognostic factor for survival.
oreover, patients with poor performance status usually do not
eneﬁt from combination or intensiﬁed chemotherapy regimens.
ouvet and co-workers compared the gemcitabine/oxaliplatin
reatments to distant metastasis and a poor PS (ECOG 2) at baseline,
howing that these factors were independent negative prognostic
actors [44]. These data were further supported in a large random-
zed phase III trial of gemcitabine and tipifarnib. ECOG performance
tatus and stage of disease (locally advanced vs. metastatic) were,ive Oncology Group Performance Status; KPS, Karnofsky Performance Status; AST,
independently of tumour differentiation and albumin level, pro-
gnostic factors negatively correlated with chemotherapy response
and clinical outcome [45].
Among several possible prognostic factors, patient age affects
survival in metastatic pancreatic cancer [46,47]. As suggested by
Aldoss et al. and Tas et al. treatment decisions must be based
on the physiological age, rather than on the chronological age.
In order to deﬁne the patient’s ﬁtness several factors must be
taken into account: functional status, co-morbidity, and cognition.
Both authors conclude that elderly patients may  be candidate for
chemotherapy provided they do not exhibit weight loss and have
a good PS [48,49].
5.2. CA 19-9
The role of CA 19-9 as a prognostic factor has later conﬁrmed in a
single centre study by Berardi et al. conducted on 181 patients with
a histological or clinical diagnosis of PDAC. The group of patients
with elevated levels of CA 19-9 at the beginning of the ﬁrst-line
chemotherapy (onset of therapy), presented a signiﬁcantly reduced
survival if compared to the others. The authors suggested the use of
CA19-9 as an additional parameter to select the most appropriate
treatment, proposing the use of intensiﬁed chemotherapy when
CA19-9 is high at the beginning [53]. A similar study conducted
by Kang et al. on 102 candidates to pancreatic resection for PDAC
showed that the pre-operative value of CA19-9 provides an estima-
tion of the risk of recurrence for both post-operative recurrences
and the choice of therapeutic strategies [54].
5.3. Prognostic models and nomograms
In 2011, Yi et al. [50] designed a prognostic model derived for
gemcitabine-based chemotherapy in PDAC patients consisting of
four prognostic factors: serum CRP levels (>1.2 mg/dl), albumin lev-
els (<3.5 g/dl), liver metastasis, and ascites dissemination. Based on
the number of factors present, the study population was divided
into three risk groups: 0–1 factor → low; 2 factors → intermediate;
3–4 factors → high risk. The survival differed notably according to
the risk-stratiﬁcation, with 10, 6.7, 4.4 months, respectively.
Hamada et al. devised a nomogram derived from the analysis of
inoperable PDAC patients receiving palliative chemotherapy [51].
Six parameters are taken into account: age, sex, ECOG performance
status, tumour size, regional lymph node and distant metastasis.
The nomogram showed to be able to provide a valid clinical out-
come for each patient with PDAC.
Recently, Xue et al. proposed a new prognostic index model
based on the retrospective analysis of 118 patients with metastatic
PDAC, who  were treated with one of the following palliative
chemotherapies: gemcitabine monotherapy, gemcitabine and cis-
platin combination therapy, gemcitabine and oxaliplatin combina-
tion therapy, gemcitabine and nab-paclitaxel combination therapy,
iver D
g
A
d
o
p
c
b
m
p
l
f
f
p
d
t
b
u
t
n
5
m
a
g
s
s
a
i
>
p
H
l
g
t
s
i
i
w
t
4
o
c
p
t
h
i
c
a
e
s
i
m
l
t
B
2
o
t
BN. Le et al. / Digestive and L
emcitabine and erlotinib combination, and S-1 monotherapy [52].
 prognostic index model was established based on three indepen-
ent variables that were signiﬁcantly negatively associated with
verall survival in a multivariable analysis: pretreatment ECOG
erformance score, CA19-9 levels, and CRP levels. The patients
lassiﬁed as low risk with this model showed signiﬁcant survival
eneﬁt from the chemotherapy, with a median survival of 9.9
onths vs. 5.3 months compared to those in the high-risk group.
In an attempt to assess the nature of the relationship between
rognostic factors and patient survival, in 2008 Stocken et al. ana-
yzed four different randomized trials proposing a novel nonlinear
ractional polynomial approach. The new model, based on trans-
ormed covariates, not only conﬁrmed ﬁve previously reported
rognostic factors (albumin, CA19-9, alkaline phosphatase, lactate
ehydrogenase and metastases), but also identiﬁed three addi-
ional possible prognostic factors not previously reported: white
lood count (WBC), aspartate aminotransferase (AST) and blood
rea nitrogen (BUN) [47]. In particular, based on this new nonlinear
ransformation approach, both CA 19-9 and LDH showed a strong
onlinear effect on survival.
.4. Genetic markers for prognosis
Studies of several regulatory pathways and the associated
olecular markers are important not only because they can offer
 better understanding of clinical outcome, but also because it can
uide the research for new molecular-based therapies. The role of
peciﬁc genetic abnormalities in PDAC is particularly complex, and
ame genetic patterns have been addressed as risk factors as well
s possible prognostic markers.
The p53, a gene that encodes for a nuclear phosphoprotein
nhibiting cell growth through activation of apoptosis, is mutated in
95% of pancreatic cancer cells. Loss of p53 is associated with aneu-
loidy, and has been proposed to be negative prognostic factor.
owever, no conclusive studies have demonstrated a convincing
ink between p53 mutation and a poorer clinical outcome [55–60].
Germline mutations of p16INK4A/p14ARF locus is a characteristic
enetic alteration observed in >80% of PDAC. This locus encodes for
wo related, and partially overlapping, suppressor genes. Several
tudies conﬁrmed the role of p16 expression as prognostic factor
n PDAC [61–65]. In particular, a lower survival has been observed
n patients with p16 mutations or hypermethylation.
A recent interest has been raised about the role of the Smad path-
ay, a signalling cascade originating from TGF- ligands. Among
he several Smad varieties, deletions of mutations of Smad 4 (locus
 or DPC4), have been reported in 55% of PDAC [66–68]. The loss
f Smad4 triggers the RB pathway with consequent increase of
ellular proliferation. Several studies have investigated so far the
ossible role of Smad4 as cellular target for tumour-suppressing
herapies. Although interesting results have been found, the studies
ave conﬁrmed that the tumour suppression through this pathway
s notably complex, and involves inhibition of tumour angiogenesis,
ell adhesion and invasion. The prognostic role of Smad4 has been
dvocated by Biankin et al., but has not been conﬁrmed by Tascilar
t al. who found opposite results. Further studies, adopting more
peciﬁc immunohistochemical analysis, are needed in order to clar-
fy the role of Smad4 as PDAC prognostic factor and therapeutic
arker [69].
Interesting ﬁndings have been reported on the role of B-cell
ymphoma-2 (Bcl-2) gene family. Among the several member of
he family, two have been strictly related to apoptosis regulation.
ax gene has been reported as an apoptosis promotes, whereas Bcl- seems to work as inhibitor. The balance between the expressions
f the two genes deﬁnes cell survival or death through an apop-
otic pathway. Different researchers have investigated the role of
cl-2 as a prognostic factor in PDAC, and surprisingly, the Bcl-2isease 48 (2016) 223–230 227
expression is remarkably correlated with a better survival. Lacasse
et al. have also studied the use of the mitochondrial pro-apoptotic
protein BNIP3, another member of the Bcl-2 family. This protein
seems to play an important role in hypoxia-induced death of nor-
mal  and malignant cells, and its expression is increased in hypoxic
regions of solid tumours [70]. As advocated in a more recent study
conducted by Erkan et al., BNIP3 is regulated by hypoxia-inducible
factor (HIF) and correlates with a worsened prognosis in pancreatic
cancer [71].
6. Treatment predictive markers in PDAC
Systemic chemotherapy for PDAC has a limited value because of
the low response rates and the severe side effects. As described
above, patients suitable for chemotherapy should be carefully
selected on the basis of speciﬁc prognostic factors in order to allo-
cate patients with poor prognosis to be treated only with supportive
therapy, avoiding unnecessary adverse effects and complications.
Predictive biomarkers for chemotherapy efﬁcacy are needed to
select patients for treatments both in the adjuvant setting and when
treating a patient with advanced disease.
6.1. Gemcitabine
The nucleoside pyrimidine analogue gemcitabine is the most
effective single agent in the palliation of advanced PDAC, where it
has been shown to improve clinical symptoms and modestly extend
survival [72]. In a study performed by Lee et al. [73] gemcitabine
chemotherapy was  found to be the only independent predictive
indicator for overall survival in patients with advanced or unre-
sectable PDAC who  had undergone a palliative surgical by pass
operation.
It is likely that individual variability of key enzymes in gem-
citabine transport and metabolism may  impact on treatment
response and toxicity of gemcitabine agents [74]. Being that gemc-
itabine is hydrophilic, the diffusion through the plasma membrane
lipid layer is slow, therefore the cellular uptake requires the pres-
ence of specialized membrane nucleoside transporter [75,76]. Two
different processes of nucleoside transport have been recognized,
and the equilibrate bidirectional facilitator (hENT) is the major
route for transporting gemcitabine. It is speculated that populations
of cells with lower hENT1 abundance may  be relatively gemcitabine
resistant, because of a reduced intracellular accumulation. Mackey
et al. [75] reported that the pharmacologic inhibition of hENT1
in cells might render them gemcitabine resistant. Other preclin-
ical studies involving PDAC cells lines have suggested a positive
correlation between hENT1 gene expression and chemosensitiv-
ity [77,78]. In a small retrospective surgical series, PDAC patients
with immunohistochemistry positivity to hENT1 showed longer
survival after gemcitabine chemotherapy than patients with pan-
creatic tumours without detectable hENT1 [79].
As reported in the recent ESPAC 1-3 trial, patients with high
hENT1 expression who  were treated with adjuvant gemcitabine
had a median overall survival signiﬁcantly longer that that of
patients with low hENT1 expression (26.2 months vs. 17.1 months)
[80]. Therefore, hENT1 expression analysis should perhaps be a
part of the routine work-up for PDAC patients, and gemcitabine
preferentially given to those with high hENT1 expression.
An on-going interventional randomized clinical trial devel-
oped by the AHS Cancer Control Alberta (Canada) is expected to
offer more insight regarding the role of hENT1 as predictive fac-
tor for treatment with Gemcitabine. Here patients lacking HENT1
expression are offered FOLFOX (5-ﬂuorouracil, leucovorin, and
oxaliplatin) instead of gemcitabine (ClinicalTrials.gov Identiﬁer:
NCT01586611). Results are expected in 2015–2016.
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.2. Fluorouracil-leucovorin-irinotecan-oxaliplatin (FOLFIRINOX)
FOLFIRINOX is a new treatment regimen in PDAC with a
ombination of folinic acid, 5-ﬂuorouracil (5-FU), irinotecan and
xaliplatin. There have been several on-going studies, which com-
are FOLFIRINOX regimen to gemcitabine within the PRODIGE
roject [81]. The PRODIGE-IV/ACCORD 11 randomized trial study,
nrolled 342 patients with ECPG grade 0–1 performance status, and
howed that FOLFIRINOX signiﬁcantly impaired the quality of life
ompared to gemcitabine, despite of prolonging the survival time.
he PRODIGE-III trial included patients less than 75 years of age
ith ECOG grade 0–1 performance status, and randomly assigned
atients with metastatic disease to receive either FOLFIRINOX or
emcitabine. The median survival in the FOLFIRINOX cohort was
1.2 months compared with 6.8 months in the gemcitabine group
82]. Currently, PRODIGE 29 has been launched, a multicentre ran-
omized phase III trial comparing adjuvant chemotherapy with
emcitabine versus FOLFIRINOX in patients with resected PDAC.
atients from more than 20 centres have been recruited.
Clinical trials have thus shown that FOLFIRINOX has a greater
fﬁcacy, but with profound limitations due to systemic toxicity and
eurotoxicity [83–85]. To date, there have been nine reported cases
f signiﬁcant central nervous system toxicity during or following
he administration of irinotecan, both with and without concur-
ent oxaliplatin. All of these cases involved the development of
ysarthria, with two of them leading to a complete motor aphasia
nd one case with associated ataxia [86–90]. Afterwards, Chandar
t al. [91] has concluded that the co-administration of irinote-
an and oxaliplatin in FOLFIRINOX regimen should be revised in
elected cases, as it may  result in severe generalized weakness
nd aphasia. It appears that this may  be triggered by underlying
nd unsuspected electrolyte disturbances. Due to this aggressive
ature, a predictive marker, which would distinguish patients who
eneﬁt the most, would be crucial and helpful for the FOLFIRI-
OX regimen. Waddell et al. have reported a small study of PDAC
atients with defective DNA maintenance. Their results showed
hat DNA maintenance defect can predict chemosensitivity to
latinum-based therapy, giving this marker a potential to be further
nvestigated in the future [92].
Irinotecan is one of FOLFIRINOX components. It is converted by
arboxylesterase enzyme to SN-38, afterwards glucuronidated in
he liver and then excreted in the bile. Originally, the main car-
oxylesterase responsible of irinotecan activation was thought to
e located in the liver, however, it has been shown that irinote-
an is a rather poor substrate for human liver carboxylesterase.
hough carboxylesteriﬁcation occurs, especially in many cancer,
ncluding PDAC, the actual pharmokinetics and pharmacodynam-
cs are poorly understood [93]. Cappello et al. investigated CES2
s a potential predictive marker for adjuvant chemotherapy with
OLFIRINOX [94]. Patients who expressed a high level of CES2 were
ssociated with longer overall survival and progression free sur-
ival. Tumour size and CES2 expression were the only predictors of
verall survival.
There currently is no other promising predictive biomarker
vailable to select patients best suited for FOLFIRINOX treatment
t the moment.
.3. Nab-paclitaxel
Nab-paclitaxel is a nanoparticle albumin-bound (nab) pacli-
axel characterized by a formulation of nanoparticle colloidal
uspension, with an average size of 130 nm,  prepared with human
erum albumin. This formulation without solvents confers more
avourable pharmacologic characteristics that allow the delivery
f a higher dose of paclitaxel [95]. Nab-paclitaxel uptake into
ells may  be dependent on SPARC expression. SPARC is generallyisease 48 (2016) 223–230
over-expressed in PDAC by stromal cells, especially in ﬁbroblasts,
but genetically silenced in the cancer cells. Given this characteristic,
Nab-paclitaxel could possibly overbridge the complex desmoplasia
in PDAC [96] that prevents efﬁcient drug delivery.
A phase I/II study was conducted in metastatic PDAC patients,
who received gemcitabine versus nab-paclitaxel. In the 44 patients
treated, median overall survival was 12.2 months and 1-year sur-
vival was 48% in the Nab-paclitaxel group. A phase III trial was
initiated after these results [97]. The MPACT trial is a phase III trial
with 861 patients [98–100]. Patients were randomized between
nab-paclitaxel and gemcitabine versus gemcitabine alone. The
overall survival was  improved with nab-paclitaxel plus gemc-
itabine arm with 8.7 months compared to 6.6 months, respectively
(p-value was  signiﬁcant <0.001), and a 1-year survival rate of 35%
vs. 22%.
Despite these promising results, there is no predictive
biomarker available to select patients best suited for Nab-paclitaxel
treatment at the moment. At the international 2015 Gastroin-
testinal Cancers Symposium by ASCO, an abstract was  presented
in which potential predictive factors were investigated [101].
These were lactate dehydrogenase (LDH) level, alkaline phos-
phatase, neutrophil/lymphocyte ratio (NLR), performance status
(PS), weight loss, presence of stent, analgesics use and CA19-9 level.
The correlation with response rate, progression-free survival (PFS)
and overall survival (OS) was  analyzed but no predictive marker
was found.
7. Conclusion
Despite recent advances in systemic treatment of patients
with advanced PDAC, the prognosis still remains poor. Thus,
pre-treatment patient selection, based on prognostic factors, for
different therapeutic options e.g. supportive care only, single-agent
chemotherapy, combination chemotherapy, may turn out to gain
clinical importance. Additionally, these prognostic factors may  also
be a useful for the design of future trials in advanced PDAC. Cur-
rently there are few predictive factors available when selecting
patients for the treatment options available, and pre-treatment
ECOG performance status is central. The advent of high-throughput
genetic and proteomic technologies such as deep sequencing have
facilitated the discovery of novel biomarkers in several other areas
of cancer medicine. If carefully applied and interpreted, these novel
technologies may  also render options to personalize treatment for
PDAC patients. An insight on the current prognostic markers and a
search for better predictive markers should guide the design and
development of future PDAC trials.
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